Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Kian‐Huat Lim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2766-200X; OpenAlex author ID A5080642100; NIH RePORTER profile ID 12479630. Sources: funder_awards.

Their work

Papers
37 (first author 7, last author 15)
Trials
0
Grants
8
Labs led
1
Collaborators
94
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers, 1 grant · 2017: 2 papers · 2018: 3 papers · 2019: 1 grant · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 8 papers · 2024: 2 papers, 2 grants · 2025: 2 papers · 2026: 5 papers, 4 grants

Papers 37

  1. Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. Co-author DOI 10.1016/j.prro.2026.03.015↗
  2. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  3. Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2026.04.017↗
  4. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  5. Editorial for PREOPANC-2, a multicenter, open-label, phase 3 randomized trial comparing neoadjuvant FOLFIRINOX vs. neoadjuvant gemcitabine based chemoradiother… First author DOI 10.21037/hbsn-2026-0282↗
  6. Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade Last author DOI 10.1101/2025.10.08.681226↗
  7. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-24-1821↗
  8. Chemokine Receptor 2 Targeted PET/CT Imaging Distant Metastases in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acsptsci.3c00303↗
  9. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Last author DOI 10.1038/s41467-024-46811-w↗
  10. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  11. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Last author DOI 10.1016/j.ijrobp.2022.07.015↗
  12. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  13. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  14. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1093/oncolo/oyac237↗
  15. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Last author DOI 10.1158/1078-0432.ccr-23-1405↗
  16. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… First author DOI 10.1158/1078-0432.ccr-23-2993↗
  17. Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for pa… First author DOI 10.1186/s40170-023-00306-2↗
  18. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2022.02.035↗
  19. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. First author DOI 10.1158/1078-0432.ccr-22-0308↗
  20. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acsnano.0c08185↗
  21. The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Last author DOI 10.1126/scitranslmed.abb5445↗
  22. Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor. Co-author DOI 10.3390/cancers13205076↗
  23. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Last author DOI 10.3390/cancers13215481↗
  24. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. Last author DOI 10.3748/wjg.v27.i18.2105↗
  25. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. First author DOI 10.1038/s41392-020-00341-1↗
  26. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Co-author DOI 10.1136/gutjnl-2018-317424↗
  27. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.11.06↗
  28. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Last author DOI 10.3390/cancers12092675↗
  29. Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-17-1366↗
  30. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Last author DOI 10.1158/1535-7163.mct-17-1142↗
  31. Pancreatic cancer survival analysis defines a signature that predicts outcome. Co-author DOI 10.1371/journal.pone.0201751↗
  32. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-16-1121↗
  33. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.15653↗
  34. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  35. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. First author DOI 10.1080/14737140.2016.1174581↗
  36. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. First author DOI 10.1177/1758834014564775↗
  37. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Co-author DOI 10.1634/theoncologist.2011-0268↗

Grants 8

  1. Core A: Administrative Core P50CA272213↗
  2. Targeting tumor innate immune signaling in pancreatic cancer R01CA219697↗
  3. Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer R01CA262414↗
  4. Research Project 2 U54CA224083↗
  5. Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy R01CA235672↗
  6. IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA R37CA219697↗
  7. Evaluation of IRAK4 As A Novel Therapeutic Target in Colorectal Cancer R21CA223112↗
  8. Deactivating the Innate Immune Defense Mechanism of Pancreatic Cancer AWARD pancan:2016-kian-huat-lim-md-phd-deactivating-the-innate-immune-defense-m

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 15 shared papers, 1 shared grant, 2016–2026 · strength 3.05
  2. Andrea Wang‐Gillam · 17 shared papers, 1 shared grant, 2012–2026 · strength 2.88
  3. William G. Hawkins · 10 shared papers, 1 shared grant, 2016–2026 · strength 2.09
  4. Ryan C Fields · 8 shared papers, 1 shared grant, 2016–2026 · strength 1.98
  5. Patrick M. Grierson · 11 shared papers, 2018–2026 · strength 1.68
  6. Paarth B. Dodhiawala · 8 shared papers, 2018–2024 · strength 1.17
  7. William E. Gillanders · 2 shared papers, 1 shared grant, 2023–2026 · strength 1.11
  8. Sapana Bansod · 5 shared papers, 2021–2026 · strength 1.04
  9. Yongjian Liu · 2 shared papers, 1 shared grant, 2021–2024 · strength 1.00
  10. Farrokh Dehdashti · 2 shared papers, 1 shared grant, 2021–2024 · strength 1.00
  11. Cynthia X Ma · 1 shared grant, 2026 · strength 1.00
  12. Ashenafi Shiferaw Bulle · 5 shared papers, 2020–2026 · strength 0.99
  13. Katrina Sophia Pedersen · 7 shared papers, 2020–2025 · strength 0.99
  14. Vikas Somani · 5 shared papers, 2022–2026 · strength 0.97
  15. Feng Gao · 5 shared papers, 2017–2026 · strength 0.63
  16. Chunjie Li · 1 shared paper, 2026 · strength 0.63
  17. Daoxiang Zhang · 6 shared papers, 2017–2023 · strength 0.63
  18. Hyun Jee Kim · 3 shared papers, 2023–2026 · strength 0.51
  19. Dominic E. Sanford · 3 shared papers, 2016–2026 · strength 0.49
  20. Roheena Z. Panni · 3 shared papers, 2016–2026 · strength 0.49
  21. John M. Baer · 3 shared papers, 2023–2025 · strength 0.47
  22. Albert Craig Lockhart · 5 shared papers, 2016–2023 · strength 0.46
  23. Carl DeSelm · 2 shared papers, 2026 · strength 0.44
  24. Jad I. Belle · 3 shared papers, 2022–2023 · strength 0.38
  25. Hongmei Jiang · 4 shared papers, 2017–2020 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.